THE UNIVERSITY OF MICHIGAN Comprehensive Cancer Center and Trovagene Inc. initiated a collaborative research program focused on the Trovera KRAS ctDNA liquid biopsy test in pancreatic cancer. “KRAS gene mutations occur in over 90 percent of pancreatic carcinomas. There is an urgent need for targeted therapies and a precision diagnostic test to identify who would...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
